Cargando…
Trans-cyclosulfamidate mannose-configured cyclitol allows isoform-dependent inhibition of GH47 α-d-mannosidases through a bump–hole strategy
Class I inverting exo-acting α-1,2-mannosidases (CAZY family GH47) display an unusual catalytic itinerary featuring ring-flipped mannosides, (3)S(1) → (3)H(4)(‡) → (1)C(4). Conformationally locked (1)C(4) compounds, such as kifunensine, display nanomolar inhibition but large multigene GH47 mannosida...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685318/ https://www.ncbi.nlm.nih.gov/pubmed/38033892 http://dx.doi.org/10.1039/d3sc05016e |
_version_ | 1785151604890009600 |
---|---|
author | Males, Alexandra Kok, Ken Nin-Hill, Alba de Koster, Nicky van den Beukel, Sija Beenakker, Thomas J. M. van der Marel, Gijsbert A. Codée, Jeroen D. C. Aerts, Johannes M. F. G. Overkleeft, Herman S. Rovira, Carme Davies, Gideon J. Artola, Marta |
author_facet | Males, Alexandra Kok, Ken Nin-Hill, Alba de Koster, Nicky van den Beukel, Sija Beenakker, Thomas J. M. van der Marel, Gijsbert A. Codée, Jeroen D. C. Aerts, Johannes M. F. G. Overkleeft, Herman S. Rovira, Carme Davies, Gideon J. Artola, Marta |
author_sort | Males, Alexandra |
collection | PubMed |
description | Class I inverting exo-acting α-1,2-mannosidases (CAZY family GH47) display an unusual catalytic itinerary featuring ring-flipped mannosides, (3)S(1) → (3)H(4)(‡) → (1)C(4). Conformationally locked (1)C(4) compounds, such as kifunensine, display nanomolar inhibition but large multigene GH47 mannosidase families render specific “isoform-dependent” inhibition impossible. Here we develop a bump-and-hole strategy in which a new mannose-configured 1,6-trans-cyclic sulfamidate inhibits α-d-mannosidases by virtue of its (1)C(4) conformation. This compound does not inhibit the wild-type GH47 model enzyme by virtue of a steric clash, a “bump”, in the active site. An L310S (a conserved residue amongst human GH47 enzymes) mutant of the model Caulobacter GH47 awoke 574 nM inhibition of the previously dormant inhibitor, confirmed by structural analysis of a 0.97 Å structure. Considering that L310 is a conserved residue amongst human GH47 enzymes, this work provides a unique framework for future biotechnological studies on N-glycan maturation and ER associated degradation by isoform-specific GH47 α-d-mannosidase inhibition through a bump-and-hole approach. |
format | Online Article Text |
id | pubmed-10685318 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Royal Society of Chemistry |
record_format | MEDLINE/PubMed |
spelling | pubmed-106853182023-11-30 Trans-cyclosulfamidate mannose-configured cyclitol allows isoform-dependent inhibition of GH47 α-d-mannosidases through a bump–hole strategy Males, Alexandra Kok, Ken Nin-Hill, Alba de Koster, Nicky van den Beukel, Sija Beenakker, Thomas J. M. van der Marel, Gijsbert A. Codée, Jeroen D. C. Aerts, Johannes M. F. G. Overkleeft, Herman S. Rovira, Carme Davies, Gideon J. Artola, Marta Chem Sci Chemistry Class I inverting exo-acting α-1,2-mannosidases (CAZY family GH47) display an unusual catalytic itinerary featuring ring-flipped mannosides, (3)S(1) → (3)H(4)(‡) → (1)C(4). Conformationally locked (1)C(4) compounds, such as kifunensine, display nanomolar inhibition but large multigene GH47 mannosidase families render specific “isoform-dependent” inhibition impossible. Here we develop a bump-and-hole strategy in which a new mannose-configured 1,6-trans-cyclic sulfamidate inhibits α-d-mannosidases by virtue of its (1)C(4) conformation. This compound does not inhibit the wild-type GH47 model enzyme by virtue of a steric clash, a “bump”, in the active site. An L310S (a conserved residue amongst human GH47 enzymes) mutant of the model Caulobacter GH47 awoke 574 nM inhibition of the previously dormant inhibitor, confirmed by structural analysis of a 0.97 Å structure. Considering that L310 is a conserved residue amongst human GH47 enzymes, this work provides a unique framework for future biotechnological studies on N-glycan maturation and ER associated degradation by isoform-specific GH47 α-d-mannosidase inhibition through a bump-and-hole approach. The Royal Society of Chemistry 2023-11-17 /pmc/articles/PMC10685318/ /pubmed/38033892 http://dx.doi.org/10.1039/d3sc05016e Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by/3.0/ |
spellingShingle | Chemistry Males, Alexandra Kok, Ken Nin-Hill, Alba de Koster, Nicky van den Beukel, Sija Beenakker, Thomas J. M. van der Marel, Gijsbert A. Codée, Jeroen D. C. Aerts, Johannes M. F. G. Overkleeft, Herman S. Rovira, Carme Davies, Gideon J. Artola, Marta Trans-cyclosulfamidate mannose-configured cyclitol allows isoform-dependent inhibition of GH47 α-d-mannosidases through a bump–hole strategy |
title |
Trans-cyclosulfamidate mannose-configured cyclitol allows isoform-dependent inhibition of GH47 α-d-mannosidases through a bump–hole strategy |
title_full |
Trans-cyclosulfamidate mannose-configured cyclitol allows isoform-dependent inhibition of GH47 α-d-mannosidases through a bump–hole strategy |
title_fullStr |
Trans-cyclosulfamidate mannose-configured cyclitol allows isoform-dependent inhibition of GH47 α-d-mannosidases through a bump–hole strategy |
title_full_unstemmed |
Trans-cyclosulfamidate mannose-configured cyclitol allows isoform-dependent inhibition of GH47 α-d-mannosidases through a bump–hole strategy |
title_short |
Trans-cyclosulfamidate mannose-configured cyclitol allows isoform-dependent inhibition of GH47 α-d-mannosidases through a bump–hole strategy |
title_sort | trans-cyclosulfamidate mannose-configured cyclitol allows isoform-dependent inhibition of gh47 α-d-mannosidases through a bump–hole strategy |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685318/ https://www.ncbi.nlm.nih.gov/pubmed/38033892 http://dx.doi.org/10.1039/d3sc05016e |
work_keys_str_mv | AT malesalexandra transcyclosulfamidatemannoseconfiguredcyclitolallowsisoformdependentinhibitionofgh47admannosidasesthroughabumpholestrategy AT kokken transcyclosulfamidatemannoseconfiguredcyclitolallowsisoformdependentinhibitionofgh47admannosidasesthroughabumpholestrategy AT ninhillalba transcyclosulfamidatemannoseconfiguredcyclitolallowsisoformdependentinhibitionofgh47admannosidasesthroughabumpholestrategy AT dekosternicky transcyclosulfamidatemannoseconfiguredcyclitolallowsisoformdependentinhibitionofgh47admannosidasesthroughabumpholestrategy AT vandenbeukelsija transcyclosulfamidatemannoseconfiguredcyclitolallowsisoformdependentinhibitionofgh47admannosidasesthroughabumpholestrategy AT beenakkerthomasjm transcyclosulfamidatemannoseconfiguredcyclitolallowsisoformdependentinhibitionofgh47admannosidasesthroughabumpholestrategy AT vandermarelgijsberta transcyclosulfamidatemannoseconfiguredcyclitolallowsisoformdependentinhibitionofgh47admannosidasesthroughabumpholestrategy AT codeejeroendc transcyclosulfamidatemannoseconfiguredcyclitolallowsisoformdependentinhibitionofgh47admannosidasesthroughabumpholestrategy AT aertsjohannesmfg transcyclosulfamidatemannoseconfiguredcyclitolallowsisoformdependentinhibitionofgh47admannosidasesthroughabumpholestrategy AT overkleefthermans transcyclosulfamidatemannoseconfiguredcyclitolallowsisoformdependentinhibitionofgh47admannosidasesthroughabumpholestrategy AT roviracarme transcyclosulfamidatemannoseconfiguredcyclitolallowsisoformdependentinhibitionofgh47admannosidasesthroughabumpholestrategy AT daviesgideonj transcyclosulfamidatemannoseconfiguredcyclitolallowsisoformdependentinhibitionofgh47admannosidasesthroughabumpholestrategy AT artolamarta transcyclosulfamidatemannoseconfiguredcyclitolallowsisoformdependentinhibitionofgh47admannosidasesthroughabumpholestrategy |